May 11, 2023
Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the first quarter ended March 31, 2023 and provided business highlights.
May 8, 2023
PHILADELPHIA, PA – May 8, 2023 – Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15 at...
May 5, 2023
Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma”), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at several healthcare industry conferences in May 2023.
April 14, 2023
Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced three abstracts were accepted for presentation at AACR Annual Meeting held from Friday, April 14 – Wednesday, April 19 in Orlando, FL.
April 6, 2023
Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will participate at several conferences in April 2023.
April 4, 2023
Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the year ended December 31, 2022 and highlighted recent business updates.